Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Oktober 2025

Genmab — Oktober 2025

Planlagt Fastgjort Låst Flyttet Genmab
427 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktør
    wrote on sidst redigeret af
    #377

    Godmorgen

    1 Reply Last reply
    0
    • B Offline
      B Offline
      bibob
      wrote on sidst redigeret af
      #378

      God morgen. 🙂

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #379

        Thanks EL. Columvi 200 mln, Ocrevy impressing +5 bn and still ca 1 bn in Rituxan

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #380

          Ocrevus has become a huge succes. Damn GSK !

          1 Reply Last reply
          0
          • W Offline
            W Offline
            w
            wrote on sidst redigeret af
            #381

            at være
            first mover, er tydeligvis vigtig

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #382

              Look fw to Novartis Q3 and Kesimpta sales.

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote on sidst redigeret af
                #383

                @w yes its important

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #384

                  And Roche salesforce are clever.

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #385

                    So for Q1 Q2 Q3 2025: Columvi

                    60 , 63 , 79 Lunsumio 21 , 27 , 29 Ocrevus 1778 , 1728 , 1690 all in CHF -if i calculate correctly...

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #386

                      Goldman Sachs has raised its target price for Genmab to 1,996 Danish kroner, up from the previous target of 1,955 Danish kroner, according to BN. The investment bank maintains its neutral rating on the stock. 10/24/2025 https://www.marketscreener.com/news/goldman-sachs-raises-target-price-for-genmab-to-1-996-danish-kroner-maintains-neutral-rating-bn-ce7d5dd9da8aff21

                      1 Reply Last reply
                      0
                      • SolsenS Offline
                        SolsenS Offline
                        Solsen
                        wrote on sidst redigeret af
                        #387

                        Thanks again EL 🙂 Interesting development in Ocrevus. Lets se Kesimpta sales over the same quaters.

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #388

                          we will get them next week

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #389

                            GSK's Blenrep's back in US, but with a narrower label https://pharmaphorum.com/news/gsks-blenreps-back-us-narrower-label

                            1 Reply Last reply
                            0
                            • R Offline
                              R Offline
                              Raffles
                              wrote on sidst redigeret af
                              #390

                              Merus er pt igang med en præsentation vedr. colorectal cancer og har udsendt lidt data. 100% response rate in 1L left-sided mCRC (n=8 confirmed and unconfirmed). 62% response rate in 2L left and right-sided mCRC (n=13, confirmed and unconfirmed). Det ser vel ganske fornuftigt ud ?? https://ir.merus.nl/news-releases/news-release-details/merus-interim-data-petosemtamab-metastatic-colorectal-cancer

                              1 Reply Last reply
                              0
                              • R Offline
                                R Offline
                                Raffles
                                wrote on sidst redigeret af
                                #391

                                Det er interim clinical data fra ongoing phase 2 studie med Petosemtamab mod Colorectal cancer. Cut off date 29/7 2025.

                                1 Reply Last reply
                                0
                                • L Offline
                                  L Offline
                                  lahn1
                                  wrote on sidst redigeret af
                                  #392

                                  Flotte men tidlige data n=24 i ph1 fra Zyme. ADC ZW191 in FRa gynecological cancer participants
                                  all dose levels → ORR 50%
                                  6.4 mg/kg to 9.6 mg/kg → 64% ORR
                                  Responses were observed in tumors with low/negative levels of FRa expression! Så kan på sigt blive en konkurrent til Rina-S

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #393

                                    Merus presentation - Petosemtamab (MCLA-158) monotherapy or with chemotherapy in metastatic colorectal cancer: Preliminary antitumor activity and safety data from a phase 2 trial - https://merus.nl/wp-content/uploads/2025/10/MCLA-158-mCRC-oral-presentation-AACR-NCI-EORTC2025-FINAL.pdf

                                    1 Reply Last reply
                                    0
                                    • R Offline
                                      R Offline
                                      Raun
                                      wrote on sidst redigeret af
                                      #394

                                      Det ser ud til at omsætningen igen er høj i US - Har de måske fokus på Merus præsentation?.... De kan i hvert fald ikke bestemme sig, hvilken vej aktien skal 🙂

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #395

                                        Lahn og et meget positivt CC - og godt at de dermed fik vallideret deres linker og payload, så er da mere håb for pipelinen. Og rart at de lader til at være åbne overfor en partner tidligt - det er nok ret fornuftigt i et efterhånden meget kompetitivt marked.

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #396

                                          Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US https://www.tandfonline.com/doi/full/10.1080/14796694.2025.2572784?src=#abstract

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper